/SYK
SYK Stock - Stryker Corporation
Healthcare|Medical - DevicesNYSE
$355.20+0.59%
+$2.09 (+0.59%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.38
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).83
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.84
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+16.3%upside
Target: $413.10
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SYK
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$351.65 – $358.75
TARGET (TP)$413.13
STOP LOSS$326.78
RISK/REWARD1:2.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.90
52W High$406.19
52W Low$329.16
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $22.59B | $20.50B | $18.45B | $17.11B | $14.35B |
| Gross Profit | $13.98B | $12.49B | $11.04B | $10.71B | $8.75B |
| Gross Margin | 61.9% | 61.0% | 59.8% | 62.6% | 61.0% |
| Operating Income | $5.06B | $4.28B | $3.73B | $3.76B | $3.03B |
| Net Income | $2.99B | $3.17B | $2.36B | $1.99B | $1.60B |
| Net Margin | 13.2% | 15.4% | 12.8% | 11.7% | 11.1% |
| EPS | $7.86 | $8.34 | $6.23 | $5.29 | $4.26 |
Company Overview
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
10
59%
Hold / Neutral
7
41%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
10 Bullish7 Neutral/Bearish
Price Targets
$331
Average Target
↓ 6.8% Downside
Now
$205
Low
$331
Average
$450
High
Based on 18 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 19th 2025 | Citizens JMP | Upgrade | Mkt Outperform | $440 |
| September 18th 2025 | Rothschild & Co Redburn | Initiation | Neutral | $420 |
| February 26th 2025 | Citigroup | Resumed | Buy | $450 |
| December 2nd 2024 | Morgan Stanley | Upgrade | Overweight | $445← $370 |
| September 10th 2024 | Wolfe Research | Initiation | Outperform | $405 |
| May 30th 2024 | Goldman | Initiation | Neutral | $372 |
| May 22nd 2024 | Needham | Upgrade | Buy | $392 |
| January 31st 2024 | Canaccord Genuity | Upgrade | Buy | $360← $315 |
| October 20th 2023 | ROTH MKM | Initiation | Buy | $345 |
| September 5th 2023 | BofA Securities | Upgrade | Buy | $315← $310 |
| March 29th 2023 | UBS | Initiation | Neutral | $287 |
| January 25th 2023 | KeyBanc Capital Markets | Initiation | Sector Weight | - |
| January 9th 2023 | RBC Capital Mkts | Upgrade | Outperform | $284← $240 |
| November 1st 2022 | Canaccord Genuity | Downgrade | Hold | $220← $225 |
| October 18th 2022 | Barclays | Initiation | Overweight | $239 |
Earnings History & Surprises
SYKBeat Rate
78%
Last 18 quarters
Avg Surprise
+2.6%
EPS vs Estimate
Beats / Misses
14/4
Last 12 quarters
Latest EPS
$3.19
Q4 2025
EPS Surprise History
Q1 24
+5.8%
$3.46vs$3.27
Q2 24
+6.4%
$2.50vs$2.35
Q3 24
+0.7%
$2.81vs$2.79
Q4 24
+3.6%
$2.87vs$2.77
Q1 25
+3.6%
$4.01vs$3.87
Q2 25
+4.8%
$2.84vs$2.71
Q3 25
+2.0%
$3.13vs$3.07
Q4 25
+1.9%
$3.19vs$3.13
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Jan 27, 2026 | $4.39 | — | — | — |
Q4 2025 | Oct 30, 2025 | $3.13 | $3.19 | +1.9% | ✓ BEAT |
Q3 2025 | Jul 31, 2025 | $3.07 | $3.13 | +2.0% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $2.71 | $2.84 | +4.8% | ✓ BEAT |
Q1 2025 | Jan 28, 2025 | $3.87 | $4.01 | +3.6% | ✓ BEAT |
Q4 2024 | Oct 29, 2024 | $2.77 | $2.87 | +3.6% | ✓ BEAT |
Q3 2024 | Jul 30, 2024 | $2.79 | $2.81 | +0.7% | ✓ BEAT |
Q2 2024 | Apr 30, 2024 | $2.35 | $2.50 | +6.4% | ✓ BEAT |
Q1 2024 | Jan 30, 2024 | $3.27 | $3.46 | +5.8% | ✓ BEAT |
Q4 2023 | Nov 2, 2023 | $2.44 | $2.46 | +0.8% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $2.38 | $2.54 | +6.7% | ✓ BEAT |
Q2 2023 | May 1, 2023 | $2.00 | $2.14 | +7.0% | ✓ BEAT |
Q1 2023 | Jan 31, 2023 | $2.84 | $3.00 | +5.6% | ✓ BEAT |
Q4 2022 | Oct 31, 2022 | $2.23 | $2.12 | -4.9% | ✗ MISS |
Q3 2022 | Jul 26, 2022 | $2.27 | $2.25 | -0.9% | ✗ MISS |
Q2 2022 | Apr 28, 2022 | $1.93 | $1.97 | +2.1% | ✓ BEAT |
Q1 2022 | Jan 27, 2022 | $2.72 | $2.71 | -0.4% | ✗ MISS |
Q4 2021 | Oct 28, 2021 | $2.28 | $2.20 | -3.5% | ✗ MISS |
Q3 2021 | Jul 27, 2021 | $2.12 | $2.25 | +6.1% | ✓ BEAT |
Latest News
Citizens Upgrades Stryker to Market Outperform, Announces $440 Price Target
📈 PositiveBenzinga•Dec 19, 2025, 01:36 PM
Trump Administration Proposes Rule Banning Medicaid And CHIP From Paying For Gender Affirming Care
➖ NeutralBenzinga•Dec 18, 2025, 04:27 PM•Also: , ,
Truist Securities Maintains Hold on Stryker, Lowers Price Target to $392
➖ NeutralBenzinga•Dec 18, 2025, 04:02 PM
Citigroup Maintains Buy on Stryker, Lowers Price Target to $420
➖ NeutralBenzinga•Dec 11, 2025, 09:06 PM•Also:
Stryker Appoints Spencer Stiles As President, Chief Operating Officer, Effective Jan. 1, 2026
➖ NeutralBenzinga•Dec 4, 2025, 01:39 PM
Truist Securities Maintains Hold on Stryker, Raises Price Target to $400
➖ NeutralBenzinga•Nov 14, 2025, 05:58 PM
Wells Fargo Maintains Overweight on Stryker, Raises Price Target to $456
📈 PositiveBenzinga•Nov 14, 2025, 03:17 PM
Needham Reiterates Buy on Stryker, Maintains $448 Price Target
📈 PositiveBenzinga•Nov 14, 2025, 10:40 AM
BTIG Reiterates Buy on Stryker, Maintains $410 Price Target
📈 PositiveBenzinga•Nov 14, 2025, 10:03 AM
Leonardo DRS Awarded Contract From Chaiseri Defense System To Offer Battle Management System, Integration Support Services To Upgrade Royal Thailand Army's Stryker Situational Awareness Capabilities
📈 PositiveBenzinga•Nov 13, 2025, 09:41 PM•Also:
Truist Securities Reiterates Hold on Stryker, Lowers Price Target to $392
➖ NeutralBenzinga•Nov 3, 2025, 03:31 PM
Evercore ISI Group Maintains Outperform on Stryker, Lowers Price Target to $405
➖ NeutralBenzinga•Oct 31, 2025, 01:44 PM
BTIG Maintains Buy on Stryker, Raises Price Target to $410
📈 PositiveBenzinga•Oct 31, 2025, 08:35 AM
Stryker shares are trading lower. The company reported Q3 financial results.
📉 NegativeBenzinga•Oct 30, 2025, 09:03 PM
Stryker Raises FY2025 Adj EPS Guidance from $13.40-$13.60 to $13.50-$13.60 vs $13.49 Est
📈 PositiveBenzinga•Oct 30, 2025, 08:06 PM
Stryker Q3 Adj. EPS $3.19 Beats $3.13 Estimate, Sales $6.057B Beat $6.046B Estimate
📈 PositiveBenzinga•Oct 30, 2025, 08:06 PM
Barclays Maintains Overweight on Stryker, Raises Price Target to $453
📈 PositiveBenzinga•Oct 22, 2025, 04:59 PM•Also:
Truist Securities Maintains Hold on Stryker, Lowers Price Target to $407
➖ NeutralBenzinga•Oct 15, 2025, 04:01 PM
BTIG Maintains Buy on Stryker, Raises Price Target to $408
📈 PositiveBenzinga•Oct 13, 2025, 12:13 PM
Evercore ISI Group Maintains Outperform on Stryker, Lowers Price Target to $410
➖ NeutralBenzinga•Oct 7, 2025, 05:55 PM
Frequently Asked Questions about SYK
What is SYK's current stock price?
Stryker Corporation (SYK) is currently trading at $355.20 per share. The stock has moved +0.59% today.
What is the analyst price target for SYK?
The average analyst price target for SYK is $413.13, based on 1 analyst.
What sector is Stryker Corporation in?
Stryker Corporation operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NYSE exchange.
What is SYK's market cap?
Stryker Corporation has a market capitalization of $135.83 billion, making it a large-cap company.
Does SYK pay dividends?
No, Stryker Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAMGN
Amgen Inc.
$327.38
Mkt Cap: $176.3B
BSX
Boston Scientific Corporation
$95.61
Mkt Cap: $141.7B
DHR
Danaher Corporation
$224.84
Mkt Cap: $161.1B
GILD
Gilead Sciences, Inc.
$124.29
Mkt Cap: $154.2B
HCA
HCA Healthcare, Inc.
$472.98
Mkt Cap: $114.8B
MCK
McKesson Corporation
$820.25
Mkt Cap: $102.5B
MDT
Medtronic plc
$98.63
Mkt Cap: $126.5B
PFE
Pfizer Inc.
$25.20
Mkt Cap: $143.3B
SNY
Sanofi
$48.18
Mkt Cap: $117.4B
VRTX
Vertex Pharmaceuticals Incorporated
$456.20
Mkt Cap: $117.1B
Explore stocks similar to SYK for comparison